1383485-63-9

Basic information

• Product Name: N-((1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide
• Synonyms: N-((1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide
• CAS NO: 1383485-63-9
• Molecular Weight: 712.777
• Mol File: 1383485-63-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide(1383485-63-9)
• EPA Substance Registry System: N-((1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide(1383485-63-9)

Safety Data

• Hazardous Substances Data: 1383485-63-9(Hazardous Substances Data)

Upstream product

• 1383446-10-3 3-bromo-5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridine 
• 1256822-80-6 3-bromo-5-fluoro-1H-pyrazolo[3,4-b]pyridine 
• 1383485-62-8 N-((1R,3S)-3-(6-bromo-3,5-difluoropyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide 
• 1383446-11-4 5-fluoro-3-(4,4,5,5-tetramethyl-1.3.2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3.4-b] pyridine 
• 1034667-22-5 5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 791644-48-9 2-chloro-5-fluoronicotinonitrile 
• 75302-64-6 2-chloro-5-fluoropyridine-3-carboxamide 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 

Downstream Products

• 1383485-79-7 N-((1R,3S)-3-(3,5-difluoro-6-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-ylamino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide 

Relevant articles and documents

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.